Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mesenchymal Stromal Cells in Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia - A Phase 2 Multi-Centre Double Blind Randomized Controlled Trial

NCT07058025 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT07058025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07058025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mesenchymal Stromal Cells in Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia - A Phase 2 Multi-Centre Double Blind Randomized Controlled Trial
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
September 30, 2038
Enrollment
168 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia (bpd), elgan (22-28sa)